Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, Brasília, DF 70910-900, Brazil.
J Mater Chem B. 2020 Dec 21;8(47):10681-10685. doi: 10.1039/d0tb02180f. Epub 2020 Nov 6.
The development of innovative nanomedicine has raised the standards over the last few decades. The establishment of research institutes with robust budgets dedicated to nanomedicine has created promise for the development of products based on biomedical applications of nanotechnology. Currently, this development meets obstacles because some of the scientific community has raised concerns regarding the launch of nanomedicine in the market. In this review highlight, we aimed to discuss some of these concerns and contribute to this discussion. For this purpose, we enumerated three issues that should be deeply discussed by the nanotech community to improve the translation of innovation from the laboratory to the market: (1) set-up more effective scaled-up industrial processes; (2) correlate data from preclinical and clinical studies with nanomedical developments; (3) optimize the incorporation of nanoparticles in a compatible final pharmaceutical form. Other issues are also important for this discussion, but we believe that these three are fundamental aspects to bridge the gap between basic nanoscience knowledge to market nanomedical innovations.
在过去几十年中，创新型纳米医学的发展提高了标准。建立了拥有雄厚预算的研究机构，专门从事纳米医学研究，为基于纳米技术的生物医学应用产品的开发带来了希望。目前，这一发展遇到了障碍，因为科学界的一些人对纳米医学推向市场提出了担忧。在这篇重点综述中，我们旨在讨论其中的一些担忧，并为这一讨论做出贡献。为此，我们列举了纳米技术界应该深入讨论的三个问题，以提高创新从实验室到市场的转化：（1）建立更有效的规模化工业流程；（2）将临床前和临床研究的数据与纳米医学的发展联系起来；（3）优化纳米颗粒在兼容的最终药物制剂中的结合。其他问题对于这一讨论也很重要，但我们认为这三个问题是弥合基础纳米科学知识与市场纳米医学创新之间差距的基本方面。
